Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Over the past 5 years, improvements in the design of antibody–drug conjugates (ADCs)
have enabled major advances that have reshaped the treatment of several advanced-stage …

Marine natural products are potent and promising sources of drugs among other natural
products of plant, animal, and microbial origin. To date, 20 drugs from marine sources are in …

Introduction We describe a new, third-generation of antibody-drug conjugates (ADCs)
having a high drug payload against topoisomerase I, important for DNA function, and …

2019 has been an excellent year in terms of peptides and oligonucleotides (TIDES)
approved by the FDA. Despite the drop in the number of total drugs approved by the FDA in …

The fact that there are now five immune checkpoint inhibitor (ICI) monoclonal antibodies
approved since 2016 that target programmed cell death protein 1 or programmed death …

Bladder cancer is the most common and lethal cancer of the urinary system. Lymphatic
metastasis is the primary and main metastatic type of bladder cancer, leading to an …

Bladder cancer (BC) is a representative of urological cancer with a high recurrence and
metastasis potential. Currently, cisplatin-based chemotherapy and immune checkpoint …

Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the cytotoxicity
of a chemical agent. They represent a rapidly evolving area of oncology drug development …

Introduction Traditional cancer therapy has many disadvantages such as low selectivity and
high toxicity of chemotherapy, as well as insufficient efficacy of targeted therapy. To enhance …